Medivir AB (OSTO:MVIR) E10: kr-2.85 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:MVIR Medivir AB OSTO:MVIR
50 GF Score
Price kr1.80
GF Value kr1.11
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Medivir AB E10?

Medivir AB OSTO:MVIR -1.10% 50 E10 is kr-2.85 as of Mar. 2026. GuruFocus rates OSTO:MVIR with a GF Score™ of 50/100 and a GF Value™ of kr1.11 (Significantly Overvalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Medivir AB's adjusted earnings per share data for the three months ended in Mar. 2026 was kr-0.020. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is kr-2.85 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Medivir AB was 13.70% per year. The lowest was -34.90% per year. And the median was 2.70% per year.

As of today (2026-08-04), Medivir AB's current stock price is kr1.80. Medivir AB's E10 for the quarter that ended in Mar. 2026 was kr-2.85. Medivir AB's Shiller PE Ratio of today is .

During the past 13 years, the highest Shiller PE Ratio of Medivir AB was 27.62. The lowest was 1.84. And the median was 9.99.


Medivir AB  (OSTO:MVIR) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

During the past 13 years, the highest Shiller P/E Ratio of Medivir AB was 27.62. The lowest was 1.84. And the median was 9.99.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Medivir AB E10 Related Terms


Medivir AB E10 Historical Data

* Premium members only.

The historical data trend for Medivir AB's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medivir AB E10 Chart

Medivir AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.90 1.44 1.41 -2.68 -2.98

Medivir AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.89 -3.13 -3.10 -2.98 -2.85

OSTO:MVIR vs VRTX, REGN, RVMD: E10 Comparison

For the Biotechnology subindustry, Medivir AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medivir AB Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medivir AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Medivir AB's Shiller PE Ratio falls into.


OSTO:MVIR
50GF Score
Medivir AB OSTO:MVIR
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medivir AB E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Medivir AB's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.02/133.5600*133.5600
=-0.020

Current CPI (Mar. 2026) = 133.5600.

Medivir AB Quarterly Data

per share eps CPI Adj_EPS
201606 -0.996 101.019 -1.317
201609 -1.258 101.138 -1.661
201612 10.306 102.022 13.492
201703 -2.415 102.022 -3.162
201706 -2.630 102.752 -3.419
201709 -2.650 103.279 -3.427
201712 -3.350 103.793 -4.311
201803 -2.132 103.962 -2.739
201806 -2.536 104.875 -3.230
201809 -1.971 105.679 -2.491
201812 -3.189 105.912 -4.021
201903 -1.547 105.886 -1.951
201906 -0.343 106.742 -0.429
201909 -0.639 107.214 -0.796
201912 -0.888 107.766 -1.101
202003 -0.787 106.563 -0.986
202006 -0.426 107.498 -0.529
202009 0.156 107.635 0.194
202012 -0.308 108.296 -0.380
202103 -0.147 108.360 -0.181
202106 -0.254 108.928 -0.311
202109 -0.197 110.338 -0.238
202112 -0.369 112.486 -0.438
202203 -0.483 114.825 -0.562
202206 -0.344 118.384 -0.388
202209 -0.221 122.296 -0.241
202212 -0.550 126.365 -0.581
202303 -0.340 127.042 -0.357
202306 -0.470 129.407 -0.485
202309 -0.420 130.224 -0.431
202312 -0.280 131.912 -0.283
202403 -0.230 132.205 -0.232
202406 -0.320 132.716 -0.322
202409 -0.300 132.304 -0.303
202412 -0.230 132.987 -0.231
202503 -0.120 132.825 -0.121
202506 -0.200 133.699 -0.200
202509 -0.130 133.480 -0.130
202512 -0.190 133.390 -0.190
202603 -0.020 133.560 -0.020

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of kr-2.85 mean?
Medivir AB (OSTO:MVIR) has a E10 of kr-2.85 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Medivir AB and its competitors.
Is Medivir AB's E10 too high?
Medivir AB's current E10 is kr-2.85. Overall, Medivir AB has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medivir AB's E10 compare to VRTX and REGN?
Medivir AB's E10 of kr-2.85 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Medivir AB and its competitors. Medivir AB's current E10 is kr-2.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medivir AB stock overvalued right now?
Based on GuruFocus' analysis, Medivir AB (OSTO:MVIR) is currently considered Significantly Overvalued. The stock's GF Value™ is kr1.11, compared to a current price of kr1.80 — trading 62.2% above its estimated fair value. The current E10 is kr-2.85. Medivir AB's overall GF Score™ is 50/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Medivir AB (OSTO:MVIR), the current E10 is kr-2.85 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medivir AB (OSTO:MVIR) Overvalued in 2026?

Based on GuruFocus' analysis, Medivir AB stock appears to be overvalued. The current stock price of kr1.80 is trading 62.2% above its estimated GF Value™ of kr1.11. GuruFocus considers Medivir AB to be Significantly Overvalued.

Key valuation signals for OSTO:MVIR:

  • E10: kr-2.85
  • GF Value™: kr1.11 vs. price of kr1.80 (62.2% above fair value)
  • GF Score™: 50/100 with 2 warning signs

No single metric tells the full story. See the OSTO:MVIR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medivir AB Business Description

Other Exchanges MVIRs:UK0GP7:UKMVR0:Germany
Address Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22
Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication that selectively delivers the cell-killing agent to the tumor while minimizing potentially harmful effects on normal cells. It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. Medivir also also has four out-licensed projects Xerclear, MIV-701, MBLI/MET-X. Geographically, it generates its maximum revenue from Europe and other regions.
50GF Score

Get the complete analysis for OSTO:MVIR

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.80
Price
kr1.11
GF Value